Tongteng Innovation （Suzhou）Co., Ltd. has invested 50 million yuan to establish a production factory in Taicang, Jiangsu. Currently, the independently developed CEL-G® has been put into operation and launched; Culture Ad60 series fixed bed bioreactor and CEL-G® TFF lab series exosome concentration system, CEL-G® TTWELDER-6 Aseptic Takeover Machine, CEL-G® The Culture Ad600 series fixed bed bioreactor provides high-quality localized cell research and production solutions for cell and gene therapy, antibody and vaccine manufacturing enterprises.

Tongteng Innovation （Suzhou）Co., Ltd. has 2 invention patents, 6 utility model patents, and 7 software copyrights. Passed ISO9001 quality management system certification, environmental management certification, occupational health and safety management certification and other qualification certifications.

The company adheres to the business philosophy of "integrity, focus, professionalism, and efficiency", and aspires to become an advanced equipment manufacturer and technology solution provider in the field of biopharmaceutical research and production.